CN102574906A - T细胞受体 - Google Patents

T细胞受体 Download PDF

Info

Publication number
CN102574906A
CN102574906A CN2010800351402A CN201080035140A CN102574906A CN 102574906 A CN102574906 A CN 102574906A CN 2010800351402 A CN2010800351402 A CN 2010800351402A CN 201080035140 A CN201080035140 A CN 201080035140A CN 102574906 A CN102574906 A CN 102574906A
Authority
CN
China
Prior art keywords
tcr
chain
amino acid
seq
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2010800351402A
Other languages
English (en)
Chinese (zh)
Inventor
B·K·雅各布森
N·哈伍德
N·R·利迪
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immunocore Ltd
Original Assignee
Immunocore Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunocore Ltd filed Critical Immunocore Ltd
Priority to CN201710535038.2A priority Critical patent/CN107266560A/zh
Priority to CN201410257886.8A priority patent/CN104017067B/zh
Publication of CN102574906A publication Critical patent/CN102574906A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3053—Skin, nerves, brain
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Neurology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN2010800351402A 2009-07-03 2010-07-01 T细胞受体 Pending CN102574906A (zh)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CN201710535038.2A CN107266560A (zh) 2009-07-03 2010-07-01 T细胞受体
CN201410257886.8A CN104017067B (zh) 2009-07-03 2010-07-01 T细胞受体

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0911566.8 2009-07-03
GBGB0911566.8A GB0911566D0 (en) 2009-07-03 2009-07-03 T cell receptors
PCT/GB2010/001277 WO2011001152A1 (en) 2009-07-03 2010-07-01 T cell receptors

Related Child Applications (2)

Application Number Title Priority Date Filing Date
CN201710535038.2A Division CN107266560A (zh) 2009-07-03 2010-07-01 T细胞受体
CN201410257886.8A Division CN104017067B (zh) 2009-07-03 2010-07-01 T细胞受体

Publications (1)

Publication Number Publication Date
CN102574906A true CN102574906A (zh) 2012-07-11

Family

ID=41008692

Family Applications (3)

Application Number Title Priority Date Filing Date
CN2010800351402A Pending CN102574906A (zh) 2009-07-03 2010-07-01 T细胞受体
CN201710535038.2A Withdrawn CN107266560A (zh) 2009-07-03 2010-07-01 T细胞受体
CN201410257886.8A Active CN104017067B (zh) 2009-07-03 2010-07-01 T细胞受体

Family Applications After (2)

Application Number Title Priority Date Filing Date
CN201710535038.2A Withdrawn CN107266560A (zh) 2009-07-03 2010-07-01 T细胞受体
CN201410257886.8A Active CN104017067B (zh) 2009-07-03 2010-07-01 T细胞受体

Country Status (19)

Country Link
US (2) US8519100B2 (enExample)
EP (1) EP2448963B1 (enExample)
JP (2) JP5872464B2 (enExample)
CN (3) CN102574906A (enExample)
AU (1) AU2010267758C1 (enExample)
BR (1) BR112012000107A2 (enExample)
CA (1) CA2766505C (enExample)
DK (1) DK2448963T3 (enExample)
EA (1) EA026918B1 (enExample)
ES (1) ES2498190T3 (enExample)
FI (1) FIC20220037I1 (enExample)
FR (1) FR22C1046I2 (enExample)
GB (1) GB0911566D0 (enExample)
LU (1) LUC00278I2 (enExample)
MX (1) MX2012000155A (enExample)
NL (1) NL301193I2 (enExample)
PT (1) PT2448963E (enExample)
WO (1) WO2011001152A1 (enExample)
ZA (1) ZA201109522B (enExample)

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014206304A1 (zh) * 2013-06-26 2014-12-31 广州市香雪制药股份有限公司 高稳定性的t细胞受体及其制法和应用
CN104853765A (zh) * 2012-11-30 2015-08-19 马克思-德布鲁克-分子医学中心（Mdc）柏林-布赫 肿瘤特异性t细胞受体
WO2015192757A1 (zh) * 2014-06-18 2015-12-23 广州市香雪制药股份有限公司 高亲和力hcv t细胞受体
CN105873945A (zh) * 2013-11-22 2016-08-17 伊利诺伊州大学理事会 工程化的高亲和力人类t细胞受体
CN107074932A (zh) * 2014-10-02 2017-08-18 美国卫生和人力服务部 分离对癌症特异性突变具有抗原特异性的t细胞受体的方法
CN107074970A (zh) * 2014-08-04 2017-08-18 弗雷德哈钦森癌症研究中心 特异性针对wt‑1的t细胞免疫疗法
CN107106670A (zh) * 2014-10-31 2017-08-29 宾夕法尼亚大学董事会 用于修饰的t细胞的方法和组合物
WO2017166005A1 (en) 2016-03-28 2017-10-05 Dow Global Technologies Llc Two-component solventless adhesive compositions and methods of making same
CN108055847A (zh) * 2015-04-20 2018-05-18 Ucl商务股份有限公司 T细胞受体
CN108602874A (zh) * 2015-09-15 2018-09-28 艾达普特免疫有限公司 Tcr文库
CN109535257A (zh) * 2017-09-22 2019-03-29 上海药明生物技术有限公司 新型双特异性cd3/cd19多肽复合物
WO2022089569A1 (en) * 2020-10-29 2022-05-05 Wuxi Biologics (Shanghai) Co., Ltd. Modified soluble t cell receptor
CN115867310A (zh) * 2020-05-05 2023-03-28 英美偌科有限公司 用于治疗癌症的识别kras g12d的抗cd3的可溶性tors和融合物
CN116322715A (zh) * 2020-05-18 2023-06-23 得克萨斯州大学系统董事会 经改造t细胞受体和使用方法
US11845796B2 (en) 2017-09-22 2023-12-19 WuXi Biologics Ireland Limited Bispecific polypeptide complexes
WO2024260454A1 (zh) * 2023-06-21 2024-12-26 北京可瑞生物科技有限公司 经修饰的tcr恒定区及其在tcr融合蛋白中的用途

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7994298B2 (en) 2004-09-24 2011-08-09 Trustees Of Dartmouth College Chimeric NK receptor and methods for treating cancer
GB0908613D0 (en) 2009-05-20 2009-06-24 Immunocore Ltd T Cell Reseptors
GB0911566D0 (en) * 2009-07-03 2009-08-12 Immunocore Ltd T cell receptors
US12492376B2 (en) 2009-10-29 2025-12-09 The Trustees Of Dartmouth College T-cell receptor-deficient T cell compositions
US9181527B2 (en) 2009-10-29 2015-11-10 The Trustees Of Dartmouth College T cell receptor-deficient T cell compositions
US9273283B2 (en) 2009-10-29 2016-03-01 The Trustees Of Dartmouth College Method of producing T cell receptor-deficient T cells expressing a chimeric receptor
US9833476B2 (en) 2011-08-31 2017-12-05 The Trustees Of Dartmouth College NKP30 receptor targeted therapeutics
JP2014530009A (ja) * 2011-09-29 2014-11-17 エーピーオー‐ティー ビー．ヴイ． 異常細胞を標的とする多重特異性結合分子
EP2802356A1 (en) 2012-01-13 2014-11-19 Apo-T B.V. Aberrant cell-restricted immunoglobulins provided with a toxic moiety
US9790278B2 (en) 2012-05-07 2017-10-17 The Trustees Of Dartmouth College Anti-B7-H6 antibody, fusion proteins, and methods of using the same
EP2897631A4 (en) 2012-08-31 2016-10-05 Univ Virginia Patent Found TARGET PEPTIDES FOR IMMUNOTHERAPY AND DIAGNOSTICS
AU2013312529A1 (en) 2012-09-05 2015-04-16 The University Of Birmingham Target peptides for colorectal cancer therapy and diagnostics
WO2014118236A2 (en) 2013-01-29 2014-08-07 Max-Delbrück-Centrum Für Moledulare Medizin (Mdc) Berlin-Buch High avidity antigen recognizing constructs
DE202014002754U1 (de) 2014-03-31 2015-07-03 Christian Piotrowski Ausgusssystem mit Pullring der mit der Folie verbunden ist.
CA2945816A1 (en) 2014-04-15 2015-10-22 University Of Virginia Patent Foundation Isolated t cell receptors and methods of use therefor
CA2955984A1 (en) 2014-07-22 2016-01-28 The University Of Notre Dame Du Lac Molecular constructs and uses thereof
GB201417803D0 (en) * 2014-10-08 2014-11-19 Adaptimmune Ltd T cell receptors
EP3215164A1 (en) 2014-11-03 2017-09-13 Immures S.r.l. T cell receptors
CN108026171A (zh) * 2015-06-01 2018-05-11 基因医疗免疫疗法有限责任公司 T细胞受体特异性抗体
HK1253694A1 (zh) * 2015-06-01 2019-06-28 Medigene Immunotherapies Gmbh T细胞受体文库
NL2014935B1 (en) 2015-06-08 2017-02-03 Applied Immune Tech Ltd T cell receptor like antibodies having fine specificity.
GB201515321D0 (en) * 2015-08-28 2015-10-14 Immatics Biotechnologies Gmbh Novel peptides, combination of peptides and scaffolds for use in immunotherapeutic treatment of various cancers
GB201516272D0 (en) 2015-09-15 2015-10-28 Adaptimmune Ltd And Immunocore Ltd TCR Libraries
ES2968802T3 (es) 2016-03-16 2024-05-14 Immatics Biotechnologies Gmbh Células T transfectadas y receptores de células T para su uso en inmunoterapia contra el cáncer
LT3430037T (lt) 2016-03-16 2022-12-12 Immatics Biotechnologies Gmbh Transfekuotos t ląstelės ir t ląstelių receptoriai, skirti naudoti vėžio gydymui taikant imunoterapiją
GB201604953D0 (en) 2016-03-23 2016-05-04 Immunocore Ltd T cell receptors
SI3464380T1 (sl) 2016-06-02 2025-03-31 Immunocore Limited Režim doziranja za gp100-specifični tcr - anti-cd3 scfv fuzijski protein
NZ750479A (en) 2016-08-17 2021-12-24 Immatics Biotechnologies Gmbh T cell receptors and immune therapy using the same
DE102016115246C5 (de) 2016-08-17 2018-12-20 Immatics Biotechnologies Gmbh Neue t-zellrezeptoren und deren verwendung in immuntherapie
JP2020501508A (ja) * 2016-09-15 2020-01-23 クアドルセプト バイオ リミテッド 多量体、四量体および八量体
GB201617714D0 (en) 2016-10-19 2016-11-30 Ucl Business Plc T Cell receptor
JP7037577B2 (ja) 2017-03-15 2022-03-16 フレッド ハッチンソン キャンサー リサーチ センター 高親和性ｍａｇｅ－ａ１特異的ｔｃｒ及びその使用
DE102017106305A1 (de) 2017-03-23 2018-09-27 Immatics Biotechnologies Gmbh Neue T-Zellrezeptoren und deren Verwendung in Immuntherapien gegen prame-positive Krebsarten
GB201709866D0 (en) * 2017-06-20 2017-08-02 Immunocore Ltd T cell receptors
US20200308279A1 (en) 2017-10-06 2020-10-01 Oslo Universitetssykehus Hf Chimeric antigen receptors
CN109776671B (zh) * 2017-11-14 2022-05-27 杭州康万达医药科技有限公司 分离的t细胞受体、其修饰的细胞、编码核酸、表达载体、制备方法、药物组合物和应用
US20210371849A1 (en) * 2018-07-31 2021-12-02 Janux Therapeutics, Inc. Inhibitory t cell receptor peptides and discovery methods
JP7558151B2 (ja) * 2018-09-05 2024-09-30 アダプティミューン・リミテッド Ｔ細胞改変
DK3911298T3 (da) 2019-01-17 2024-01-29 Immunocore Ltd Formuleringer
GB201901305D0 (en) 2019-01-30 2019-03-20 Immunocore Ltd Specific binding molecules
GB201901306D0 (en) 2019-01-30 2019-03-20 Immunocore Ltd Multi-domain binding molecules
GB201902277D0 (en) 2019-02-19 2019-04-03 King S College London Therapeutic agents
WO2020247871A2 (en) * 2019-06-06 2020-12-10 Janux Therapeutics, Inc. Compositions and methods relating to tumor activated t cell engagers
TW202118781A (zh) * 2019-07-30 2021-05-16 大學健康網絡 Ｉｉ類ｍｈｃ分子及其使用方法
CN111234004B (zh) * 2020-02-28 2023-03-28 陕西九州新药评价研究有限公司(西安新药评价研究中心) 识别wt1抗原短肽的t细胞受体及其应用
CN114853879A (zh) * 2021-02-03 2022-08-05 香雪生命科学技术（广东）有限公司 一种识别hpv的t细胞受体
WO2022258606A1 (en) 2021-06-07 2022-12-15 Gadeta B.V. Delta T-cell or Gamma T-cell receptor chains or parts thereof that mediate an anti-tumour or anti-infective response
US12103971B2 (en) 2022-02-20 2024-10-01 Immunocore Limited HIV specific binding molecules
WO2023227594A1 (en) 2022-05-24 2023-11-30 Gadeta Bv Novel deltat-cell receptor chains, gammat-cell receptor chains, or parts thereof
WO2023237541A1 (en) 2022-06-07 2023-12-14 Gadeta B.V. Delta t-cell or gamma t-cell receptor chains or parts thereof that mediate an anti-tumour or anti-infective response
WO2023246911A1 (zh) * 2022-06-24 2023-12-28 北京可瑞生物科技有限公司 基于t细胞受体的双特异性多肽分子及其用途
US20240075068A1 (en) 2022-07-15 2024-03-07 Gadeta B.V. Novel soluble gamma T-cell (or soluble delta T-cell) receptor chains (or soluble gammadelta T-cell receptors) or fragments thereof that mediate an anti-tumour or an anti-infective response
CA3264727A1 (en) 2022-08-18 2024-02-22 Immunocore Limited MULTI-DOMAIN BONDING MOLECULES
AU2023326819A1 (en) 2022-08-18 2025-03-06 Immunocore Limited Multi-domain binding molecules
AU2023326804A1 (en) 2022-08-18 2025-03-06 Immunocore Limited Multi-domain binding molecules
WO2024067821A1 (zh) * 2022-09-30 2024-04-04 瑅安生物医药（杭州）有限公司 一种修饰细胞及其用途
EP4634216A1 (en) 2022-12-16 2025-10-22 Repertoire Immune Medicines, Inc. T cell receptors binding hpv-16 epitopes
GB202315181D0 (en) 2023-10-03 2023-11-15 Immunocore Ltd Peptide-HLA binding molecules
TW202530269A (zh) * 2023-10-27 2025-08-01 大陸商北京可瑞生物科技有限公司 基於ｔ細胞受體的多特異性多肽分子及其組合物和用途
WO2025094054A1 (en) 2023-11-01 2025-05-08 Immunocore Limited Method for purifying small multi-domain proteins
GB202320012D0 (en) 2023-12-22 2024-02-07 Immunocore Ltd Bispecific molecules
CN118108833B (zh) * 2024-03-12 2025-05-02 缇纱(合肥)生物技术有限公司 引入外源二硫键的tcr恒定区及其产品和应用
WO2025224692A1 (en) 2024-04-25 2025-10-30 Immunocore Limited Method of treating cancer using a gene expression signature
GB2641580A (en) 2024-06-07 2025-12-10 T Therapeutics Ltd Tumour-transforming multispecific proteins

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999060120A2 (en) * 1998-05-19 1999-11-25 Avidex Limited Soluble t cell receptor
WO2004048410A2 (en) * 2002-11-22 2004-06-10 Isis Innovation Limited T-cell receptors
CN1561343A (zh) * 2001-08-31 2005-01-05 艾维德克斯有限公司 可溶性t细胞受体
WO2006054096A2 (en) * 2004-11-18 2006-05-26 Avidex Ltd Soluble bifunctional proteins
CN101415827A (zh) * 2005-12-09 2009-04-22 阿哥斯医疗公司 产生抗原特异性效应t细胞的方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5688747A (en) 1994-08-22 1997-11-18 Becton Dickinson And Company Water based lubricant solution
US6759243B2 (en) 1998-01-20 2004-07-06 Board Of Trustees Of The University Of Illinois High affinity TCR proteins and methods
WO2004044004A2 (en) 2002-11-09 2004-05-27 Avidex Limited T cell receptor display
US7534427B2 (en) * 2002-12-31 2009-05-19 Immunomedics, Inc. Immunotherapy of B cell malignancies and autoimmune diseases using unconjugated antibodies and conjugated antibodies and antibody combinations and fusion proteins
CN101035561A (zh) * 2004-03-24 2007-09-12 特罗斯药品公司 作为改善对疫苗的免疫反应的佐剂的组合物和使用方法
GB0411125D0 (en) * 2004-05-19 2004-06-23 Avidex Ltd Method of improving T-cell receptors
JP4972549B2 (ja) 2004-05-19 2012-07-11 イムノコア リミテッド Ｔ細胞レセプターを改善する方法
ATE475669T1 (de) 2004-06-29 2010-08-15 Immunocore Ltd Einen modifizierten t-zellen-rezeptor exprimierende zellen
US20060045884A1 (en) * 2004-08-26 2006-03-02 Board Of Regents Vaccines for autoimmune and infectious disease
CA2580412A1 (en) * 2004-09-13 2006-03-23 Government Of The United States Of America, Represented By The Secretary , Department Of Health And Human Services Compositions comprising t cell receptors and methods of use thereof
ES2829566T3 (es) * 2005-03-03 2021-06-01 Immunomedics Inc Anticuerpos L243 humanizados
GB0511124D0 (en) 2005-06-01 2005-07-06 Avidex Ltd High affinity melan-a t cell receptors
PT2016102E (pt) 2006-05-03 2012-05-15 Us Gov Health & Human Serv Recetores de célula t quimérica e materiais relacionados e métodos de uso
WO2008038002A2 (en) 2006-09-29 2008-04-03 Medigene Limited T cell therapies
US8216565B2 (en) 2007-01-12 2012-07-10 The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services GP100-specific T cell receptors and related materials and methods of use
GB0911566D0 (en) * 2009-07-03 2009-08-12 Immunocore Ltd T cell receptors

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999060120A2 (en) * 1998-05-19 1999-11-25 Avidex Limited Soluble t cell receptor
CN1561343A (zh) * 2001-08-31 2005-01-05 艾维德克斯有限公司 可溶性t细胞受体
WO2004048410A2 (en) * 2002-11-22 2004-06-10 Isis Innovation Limited T-cell receptors
WO2006054096A2 (en) * 2004-11-18 2006-05-26 Avidex Ltd Soluble bifunctional proteins
CN101415827A (zh) * 2005-12-09 2009-04-22 阿哥斯医疗公司 产生抗原特异性效应t细胞的方法

Cited By (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104853765A (zh) * 2012-11-30 2015-08-19 马克思-德布鲁克-分子医学中心（Mdc）柏林-布赫 肿瘤特异性t细胞受体
CN104853765B (zh) * 2012-11-30 2019-06-28 马克思-德布鲁克-分子医学中心（Mdc）柏林-布赫 肿瘤特异性t细胞受体
US10683336B2 (en) 2012-11-30 2020-06-16 Max-Delbrüeck-Centrum Für Molekulare Medizin (MDC) Berlin-Buch Tumor specific T-cell receptors
CN105683215A (zh) * 2013-06-26 2016-06-15 广州市香雪制药股份有限公司 高稳定性的t细胞受体及其制法和应用
US10654906B2 (en) 2013-06-26 2020-05-19 Guangdong Xiangxue Life Sciences, Ltd. High-stability T-cell receptor and preparation method and application thereof
AU2014301777B2 (en) * 2013-06-26 2017-03-30 Xlifesc, Ltd. High-stability T-cell receptor and preparation method and application thereof
WO2014206304A1 (zh) * 2013-06-26 2014-12-31 广州市香雪制药股份有限公司 高稳定性的t细胞受体及其制法和应用
CN105683215B (zh) * 2013-06-26 2021-04-23 香雪生命科学技术（广东）有限公司 高稳定性的t细胞受体及其制法和应用
CN105873945B (zh) * 2013-11-22 2020-07-17 伊利诺伊州大学理事会 工程化的高亲和力人类t细胞受体
CN105873945A (zh) * 2013-11-22 2016-08-17 伊利诺伊州大学理事会 工程化的高亲和力人类t细胞受体
US10344075B2 (en) 2013-11-22 2019-07-09 The Board Of Trustees Of The University Of Illinois Engineered high-affinity human t cell receptors
CN106459176B (zh) * 2014-06-18 2018-07-06 广东香雪精准医疗技术有限公司 高亲和力hcv t细胞受体
CN106459176A (zh) * 2014-06-18 2017-02-22 广州市香雪制药股份有限公司 高亲和力 hcv t细胞受体
WO2015192757A1 (zh) * 2014-06-18 2015-12-23 广州市香雪制药股份有限公司 高亲和力hcv t细胞受体
CN107074970B (zh) * 2014-08-04 2021-07-30 弗雷德哈钦森癌症研究中心 特异性针对wt-1的t细胞免疫疗法
CN107074970A (zh) * 2014-08-04 2017-08-18 弗雷德哈钦森癌症研究中心 特异性针对wt‑1的t细胞免疫疗法
CN107074932A (zh) * 2014-10-02 2017-08-18 美国卫生和人力服务部 分离对癌症特异性突变具有抗原特异性的t细胞受体的方法
CN107106670A (zh) * 2014-10-31 2017-08-29 宾夕法尼亚大学董事会 用于修饰的t细胞的方法和组合物
CN108055847A (zh) * 2015-04-20 2018-05-18 Ucl商务股份有限公司 T细胞受体
CN108602874A (zh) * 2015-09-15 2018-09-28 艾达普特免疫有限公司 Tcr文库
CN108602874B (zh) * 2015-09-15 2022-08-19 英美偌科有限公司 Tcr文库
WO2017166005A1 (en) 2016-03-28 2017-10-05 Dow Global Technologies Llc Two-component solventless adhesive compositions and methods of making same
CN109535257A (zh) * 2017-09-22 2019-03-29 上海药明生物技术有限公司 新型双特异性cd3/cd19多肽复合物
US11365254B2 (en) 2017-09-22 2022-06-21 WuXi Biologics Ireland Limited Bispecific CD3/CD19 polypeptide complexes
US11845796B2 (en) 2017-09-22 2023-12-19 WuXi Biologics Ireland Limited Bispecific polypeptide complexes
CN115867310A (zh) * 2020-05-05 2023-03-28 英美偌科有限公司 用于治疗癌症的识别kras g12d的抗cd3的可溶性tors和融合物
CN116322715A (zh) * 2020-05-18 2023-06-23 得克萨斯州大学系统董事会 经改造t细胞受体和使用方法
WO2022089569A1 (en) * 2020-10-29 2022-05-05 Wuxi Biologics (Shanghai) Co., Ltd. Modified soluble t cell receptor
WO2024260454A1 (zh) * 2023-06-21 2024-12-26 北京可瑞生物科技有限公司 经修饰的tcr恒定区及其在tcr融合蛋白中的用途

Also Published As

Publication number Publication date
ZA201109522B (en) 2013-05-29
AU2010267758B2 (en) 2014-09-04
US9068178B2 (en) 2015-06-30
EP2448963B1 (en) 2014-06-04
EA026918B1 (ru) 2017-05-31
JP2016039812A (ja) 2016-03-24
WO2011001152A1 (en) 2011-01-06
JP5872464B2 (ja) 2016-03-01
GB0911566D0 (en) 2009-08-12
LUC00278I2 (enExample) 2025-05-12
MX2012000155A (es) 2012-06-28
AU2010267758C1 (en) 2015-01-22
EA201270135A1 (ru) 2012-09-28
CN104017067A (zh) 2014-09-03
CA2766505C (en) 2019-01-22
NL301193I1 (enExample) 2022-08-17
FR22C1046I1 (fr) 2022-10-14
US8519100B2 (en) 2013-08-27
JP6186412B2 (ja) 2017-08-23
DK2448963T3 (da) 2014-08-25
ES2498190T3 (es) 2014-09-24
FR22C1046I2 (fr) 2025-04-04
FIC20220037I1 (fi) 2022-08-31
HK1169422A1 (en) 2013-01-25
CN107266560A (zh) 2017-10-20
US20120225481A1 (en) 2012-09-06
AU2010267758A1 (en) 2012-02-09
NL301193I2 (nl) 2022-11-24
JP2012531904A (ja) 2012-12-13
BR112012000107A2 (pt) 2016-11-01
EP2448963A1 (en) 2012-05-09
PT2448963E (pt) 2014-09-01
US20140099699A1 (en) 2014-04-10
CA2766505A1 (en) 2011-01-06
CN104017067B (zh) 2017-11-03

Similar Documents

Publication Publication Date Title
CN102574906A (zh) T细胞受体
KR102267345B1 (ko) Ｔ 세포 수용체
KR102747867B1 (ko) T 세포 수용체
JP6751391B2 (ja) Ｔ細胞受容体
US20240010702A1 (en) T cell receptors
CN110023330A (zh) T细胞受体
KR20160058767A (ko) Ｔ 세포 수용체
WO2013041865A1 (en) T cell receptors
CN103097407A (zh) T细胞受体
CN106459177B (zh) 高亲和力ny-eso t细胞受体
HK1169422B (en) T cell receptors
NZ787034A (en) T Cell Receptors

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20120711